TBXT and neurodegenerative disease: Remarkably, 62 in the range of concentrations of 0.2–5 μM suppressed τ phosphorylation in DYRK1A-overexpressing cells in a dose-dependent manner and the phosphorylation of endogenous τ in primary hippocampal neurons, confirming its therapeutic potential for a wide range of disorders involving progressive or permanent neuronal loss such as neurodegenerative diseases and traumatic brain injury [57].